These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 26750774)

  • 21. Flow cytometry analysis with a new FITC-conjugated monoclonal antibody-3E12 for HLA-B*57:01 rapid screening in prevention of abacavir hypersensitivity in HIV-1-infected patients.
    Rodríguez-Sáinz C; Valor L; Hernández DC; Gil J; Carbone J; Pascual-Bernaldez M; Rodríguez-Alcántara F; Martínez I; Vicario JL; Mallal S; Fernández-Cruz E
    HIV Clin Trials; 2013; 14(4):160-4. PubMed ID: 23924588
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [HLA-B*5701 and hypersensitivity reactions to abacavir. Study methods and clinical relevance].
    Arnedo Valero M
    Enferm Infecc Microbiol Clin; 2008 May; 26 Suppl 6():34-9. PubMed ID: 18680694
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HLA-B*57:01 screening and hypersensitivity reaction to abacavir between 1999 and 2016 in the OPERA
    Mounzer K; Hsu R; Fusco JS; Brunet L; Henegar CE; Vannappagari V; Stainsby CM; Shaefer MS; Ragone L; Fusco GP
    AIDS Res Ther; 2019 Jan; 16(1):1. PubMed ID: 30651100
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Prevalence of human leukocyte antigen (HLA)-B*57:01 in HIV-infected patients].
    Deveci A; Çoban AY; Durupınar B
    Mikrobiyol Bul; 2016 Oct; 50(4):544-551. PubMed ID: 28124959
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Incidence of abacavir hypersensitivity and its relationship with HLA-B*5701 in HIV-infected patients in Taiwan.
    Sun HY; Hung CC; Lin PH; Chang SF; Yang CY; Chang SY; Chang SC
    J Antimicrob Chemother; 2007 Sep; 60(3):599-604. PubMed ID: 17631508
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A simple screening approach to reduce B*5701-associated abacavir hypersensitivity on the basis of sequence variation in HIV reverse transcriptase.
    Chui CK; Brumme ZL; Brumme CJ; Yip B; Phillips EJ; Montaner JS; Harrigan PR
    Clin Infect Dis; 2007 Jun; 44(11):1503-8. PubMed ID: 17479950
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Abacavir Hypersensitivity Reaction Reporting Rates During a Decade of HLA-B*5701 Screening as a Risk-Mitigation Measure.
    Stainsby CM; Perger TM; Vannappagari V; Mounzer KC; Hsu RK; Henegar CE; Oyee J; Urbaityte R; Lane CE; Carter LM; Pakes GE; Shaefer MS
    Pharmacotherapy; 2019 Jan; 39(1):40-54. PubMed ID: 30414209
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study.
    Rauch A; Nolan D; Martin A; McKinnon E; Almeida C; Mallal S
    Clin Infect Dis; 2006 Jul; 43(1):99-102. PubMed ID: 16758424
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of patch testing for the diagnosis of abacavir-related hypersensitivity reaction in HIV patients.
    Giorgini S; Martinelli C; Tognetti L; Carocci A; Giuntini R; Mastronardi V; Torricelli F; Leoncini F; Lotti T
    Dermatol Ther; 2011; 24(6):591-4. PubMed ID: 22515676
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HLA-B*5701 screening for hypersensitivity to abacavir.
    Mallal S; Phillips E; Carosi G; Molina JM; Workman C; Tomazic J; Jägel-Guedes E; Rugina S; Kozyrev O; Cid JF; Hay P; Nolan D; Hughes S; Hughes A; Ryan S; Fitch N; Thorborn D; Benbow A;
    N Engl J Med; 2008 Feb; 358(6):568-79. PubMed ID: 18256392
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Refining abacavir hypersensitivity diagnoses using a structured clinical assessment and genetic testing in the Swiss HIV Cohort Study.
    Rauch A; Nolan D; Thurnheer C; Fux CA; Cavassini M; Chave JP; Opravil M; Phillips E; Mallal S; Furrer H;
    Antivir Ther; 2008; 13(8):1019-28. PubMed ID: 19195327
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A study of HIV provider attitudes toward HLA-B 5701 testing in the United States.
    Watson ME; Patel LG; Ha B; Wannamaker P; Cuffe R; Shaefer M
    AIDS Patient Care STDS; 2009 Nov; 23(11):957-63. PubMed ID: 19839743
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HLA-B*5701 typing: evaluation of an allele-specific polymerase chain reaction melting assay.
    Hammond E; Mamotte C; Nolan D; Mallal S
    Tissue Antigens; 2007 Jul; 70(1):58-61. PubMed ID: 17559582
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Value of the HLA-B*5701 allele to predict abacavir hypersensitivity in Spaniards.
    Rodríguez-Nóvoa S; García-Gascó P; Blanco F; González-Pardo G; Castellares C; Moreno V; Jiménez-Nácher I; González-Lahoz J; Soriano V
    AIDS Res Hum Retroviruses; 2007 Nov; 23(11):1374-6. PubMed ID: 18184080
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Frequency of HLA B*5701 allele carriers in abacavir treated-HIV infected patients and controls from northeastern Brazil.
    Crovella S; Biller L; Santos S; Salustiano A; Brandao L; Guimaraes R; Segat L; Lima Filho JL; Arraes LC
    Clinics (Sao Paulo); 2011; 66(8):1485-8. PubMed ID: 21915505
    [No Abstract]   [Full Text] [Related]  

  • 36. High correlation between the Roche COBAS® AmpliPrep/COBAS® TaqMan® HIV-1, v2.0 and the Abbott m2000 RealTime HIV-1 assays for quantification of viral load in HIV-1 B and non-B subtypes.
    Karasi JC; Dziezuk F; Quennery L; Förster S; Reischl U; Colucci G; Schoener D; Seguin-Devaux C; Schmit JC
    J Clin Virol; 2011 Nov; 52(3):181-6. PubMed ID: 21813320
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rapid, Reliable, and Inexpensive
    Huh JY; Han OJ; Park G
    Ann Clin Lab Sci; 2018 May; 48(3):296-300. PubMed ID: 29970431
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of multiplex pyrosequencing for HLA-B*57:01 screening using single nucleotide polymorphism haplotype.
    Sankuntaw N; Chantarangsu S; Chantratita W; Sungkanuparph S; Kiertiburanakul S; Lulitanond V
    J Clin Pharm Ther; 2014 Oct; 39(5):545-50. PubMed ID: 24861233
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HLA-B*57: 01 genotyping in the prevention of hypersensitivity to abacavir: 5 years of experience.
    Ruiz-Iruela C; Padullés-Zamora N; Podzamczer-Palter D; Alonso-Pastor A; Candás-Estébanez B; Alía-Ramos P; Padró-Miquel A
    Pharmacogenet Genomics; 2016 Aug; 26(8):390-6. PubMed ID: 27195528
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Successful implementation of a national HLA-B*5701 genetic testing service in Canada.
    Lalonde RG; Thomas R; Rachlis A; Gill MJ; Roger M; Angel JB; Smith G; Higgins N; Trottier B
    Tissue Antigens; 2010 Jan; 75(1):12-8. PubMed ID: 19843279
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.